# CDH6

Source: https://onco.cc/targets/cdh6/  
OnCo record `cdh6` (Target). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

CDH6 is an adhesion protein from kidney development that reappears on ovarian and kidney cancers.

## Summary

Cadherin-6 (CDH6) is a type II cadherin and a fetal kidney marker that is overexpressed in ovarian cancer and renal cell carcinoma with low normal adult expression, the profile an ADC target needs. It is found in 65-85% of ovarian cancers, particularly high-grade serous, and 60-80% of renal cell carcinomas by IHC. Raludotatug deruxtecan (R-DXd), a CDH6 ADC with the DXd payload, is in phase 3 in platinum-resistant ovarian cancer (REJOICE-Ovarian01). The main open question is whether the DXd payload's interstitial lung disease signal and the expression threshold for benefit will hold up in a randomised setting. The simple version is an adhesion protein from kidney development that reappears on ovarian and kidney cancers, giving an ADC a clean address.

## Fields

- Kind: Target
- Last checked: 2026-09-04
- Tags: adc-target
- Symbol: CDH6
- Class: surface-antigen
- Biology: CDH6 is a type II cadherin and a fetal kidney marker.
- Where found: Ovarian; Renal cell carcinoma

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/CDH6
- Wikipedia: https://en.wikipedia.org/wiki/CDH6

## Connected records

- cancers: [Ovarian cancer](https://onco.cc/cancers/ovarian/), [Renal cell carcinoma](https://onco.cc/cancers/rcc/)
- drugs: [Raludotatug deruxtecan](https://onco.cc/drugs/raludotatug-deruxtecan/)
- trials: [REJOICE-Ovarian01](https://onco.cc/trials/rejoice-ovarian01/)
- technologies: [Antibody-drug conjugate (ADC)](https://onco.cc/technologies/adc/)

---
JSON: https://onco.cc/api/v1/entities/cdh6.json